RNA recombination at Chikungunya virus 3'UTR as an evolutionary mechanism that provides adaptability.

08:00 EDT 15th April 2019 | BioPortfolio

Summary of "RNA recombination at Chikungunya virus 3'UTR as an evolutionary mechanism that provides adaptability."

The potential of RNA viruses to adapt to new environments relies on their ability to introduce changes in their genomes, which has resulted in the recent expansion of re-emergent viruses. Chikungunya virus is an important human pathogen transmitted by mosquitoes that, after 60 years of exclusive circulation in Asia and Africa, has rapidly spread in Europe and the Americas. Here, we examined the evolution of CHIKV in different hosts and uncovered host-specific requirements of the CHIKV 3'UTR. Sequence repeats are conserved at the CHIKV 3'UTR but vary in copy number among viral lineages. We found that these blocks of repeated sequences favor RNA recombination processes through copy-choice mechanism that acts concertedly with viral selection, determining the emergence of new viral variants. Functional analyses using a panel of mutant viruses indicated that opposite selective pressures in mosquito and mammalian cells impose a fitness cost during transmission that is alleviated by recombination guided by sequence repeats. Indeed, drastic changes in the frequency of viral variants with different numbers of repeats were detected during host switch. We propose that RNA recombination accelerates CHIKV adaptability, allowing the virus to overcome genetic bottlenecks within the mosquito host. These studies highlight the role of 3'UTR plasticity on CHIKV evolution, providing a new paradigm to explain the significance of sequence repetitions.


Journal Details

This article was published in the following journal.

Name: PLoS pathogens
ISSN: 1553-7374
Pages: e1007706


DeepDyve research library

PubMed Articles [10526 Associated PubMed Articles listed on BioPortfolio]

Antiviral activity of ethanolic extract of Nilavembu Kudineer against dengue and chikungunya virus through in vitro evaluation.

Currently, no vaccines or modern drugs are available for dengue and chikungunya and only symptomatic relief is provided to the patients. Siddha medicine, a traditional form of indigenous medical syste...

A systematic review of individual and community mitigation measures for prevention and control of chikungunya virus.

Chikungunya is a mosquito-borne virus transmitted by mosquitoes from the Aedes genus. The virus, endemic to parts of Asia and Africa, has recently undergone an emergence in other parts of the world wh...

Virus load and clinical features during the acute phase of Chikungunya infection in children.

Chikungunya virus (CHIKV) infection is a long known mosquito-borne disease that is associated with severe morbidity, characterized by fever, headache, rashes, joint pain, and myalgia. It is believed t...

Outbreak Of Chikungunya Virus In Karachi, Pakistan.

In this report, aim is to highlight the recent outbreak of Chikungunya virus in Karachi, the largest city of Pakistan. Chikungunya virus is transmitted by infected Aedes mosquitoes. Firstly, described...

Peptide vaccine against chikungunya virus: immuno-informatics combined with molecular docking approach.

Chikungunya virus (CHIKV), causes massive outbreaks of chikungunya infection in several regions of Asia, Africa and Central/South America. Being positive sense RNA virus, CHIKV replication within the ...

Clinical Trials [3653 Associated Clinical Trials listed on BioPortfolio]

The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico

This study will evaluate subjects with fever and/or rash to determine the percentage of those infected by the Zika, Chikungunya, or Dengue virus. The study will also compare the clinical s...

Chikungunya Vaccine Study in Previously Exposed Adults

Safety and immunogenicity of an investigational chikungunya vaccine will be tested in subjects with history of chikungunya infection. Initially 21 to 50 year old subjects will be enrolled;...

Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults

This is a multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety and immunogenicity of a 2 injection vaccine Chikungunya virus (CHIKV) and virus like partic...

Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine

The purpose of this study is to evaluate the immunogenicity and safety of a novel vaccine against Chikungunya virus after one or two vaccinations by comparison of two different dose levels...

Study of the Prognostic Value of Musculoskeletal Ultrasound in Adults With Chikungunya

Chikungunya is a viral disease transmitted by mosquitoes whose clinical feature is the early joint damage. Approximately 8% of patients have chronic arthropathy resembling to the rheumatoi...

Medical and Biotech [MESH] Definitions


A species of ALPHAVIRUS causing a measles-like acute febrile rash illness. It is closely related to the Chikungunya virus and Igbo Ora viruses.

A species of ALPHAVIRUS causing an acute dengue-like fever.

The termination of the cell's ability to carry out vital functions such as metabolism, growth, reproduction, responsiveness, and adaptability.

The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.

Quick Search


DeepDyve research library

Searches Linking to this Article